Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical Research for Real-World Patients

Biotech Investing

Syneos Health (NASDAQ:SYNH) has announced that it and Elligo Health Research have entered into a strategic collaboration to mobilize a system of accelerated research to reach real-world patients. As quoted in the press release: Syneos Health is a top three Contract Research Organization (CRO) that combines comprehensive and integrated outsourcing solutions for both clinical development …

Syneos Health (NASDAQ:SYNH) has announced that it and Elligo Health Research have entered into a strategic collaboration to mobilize a system of accelerated research to reach real-world patients.

As quoted in the press release:

Syneos Health is a top three Contract Research Organization (CRO) that combines comprehensive and integrated outsourcing solutions for both clinical development and commercialization. Elligo Health Research deploys an approach that improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients.

Applying its Goes Direct® approach, Elligo identifies patients for clinical trials using electronic health records and then provides their physicians with the infrastructure to conduct the research in their own practices. This platform enables research at practices that historically would not have had the infrastructure to conduct clinical research. Syneos Health will collaborate with Elligo to pilot new ways of quickly finding patients to enlist them in clinical trial research.

The collaboration will seek to build a centrally managed infrastructure and regulatory research system around physicians and patients who have not typically been accessible in traditional sites. This could include deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden and focusing the experience around the patient.

The ability to bring clinical research to underrepresented populations through community medical practices, evolving from a location-bound approach, to a centrally managed systemic approach, redefines the clinical trial site footprint. This effort should improve quality, reduce timelines and save costs.

Click here to read the full press release.

The Conversation (0)
×